Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $35.10.

A number of equities research analysts have recently commented on RCUS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Monday, April 20th. The Goldman Sachs Group lifted their target price on Arcus Biosciences from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Morgan Stanley boosted their target price on Arcus Biosciences from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Monday, May 11th. Citigroup upped their target price on Arcus Biosciences from $44.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Finally, Lifesci Capital began coverage on Arcus Biosciences in a research report on Thursday, June 4th. They issued an “outperform” rating and a $46.00 price target for the company.

Insider Buying and Selling at Arcus Biosciences

In other news, President Juan C. Jaen sold 6,431 shares of Arcus Biosciences stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $29.66, for a total value of $190,743.46. Following the transaction, the president directly owned 890,809 shares of the company’s stock, valued at $26,421,394.94. This trade represents a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Alexander Azoy sold 2,562 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $25.77, for a total transaction of $66,022.74. Following the sale, the chief accounting officer owned 39,581 shares in the company, valued at $1,020,002.37. This represents a 6.08% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 41,756 shares of company stock valued at $1,142,517. 9.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Arcus Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RCUS. Hantz Financial Services Inc. grew its position in Arcus Biosciences by 121.9% during the 4th quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock worth $38,000 after purchasing an additional 881 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Arcus Biosciences in the fourth quarter valued at $39,000. KBC Group NV purchased a new stake in shares of Arcus Biosciences in the first quarter valued at $50,000. Strs Ohio acquired a new stake in shares of Arcus Biosciences in the first quarter worth $67,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Arcus Biosciences by 184.2% in the second quarter. Tower Research Capital LLC TRC now owns 8,449 shares of the company’s stock worth $69,000 after buying an additional 5,476 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Stock Up 5.2%

RCUS stock opened at $30.42 on Friday. The firm has a market cap of $3.83 billion, a PE ratio of -9.57 and a beta of 0.80. Arcus Biosciences has a 12 month low of $8.03 and a 12 month high of $31.74. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.04 and a quick ratio of 4.04. The firm has a 50 day simple moving average of $25.34 and a 200 day simple moving average of $23.16.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.10). The business had revenue of $17.00 million during the quarter, compared to analyst estimates of $29.48 million. Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The company’s quarterly revenue was down 39.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.14) EPS. Equities research analysts forecast that Arcus Biosciences will post -3.66 earnings per share for the current fiscal year.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.